Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Doxorubicin
Drug: Bortezomib
Drug: Filgrastim

First Posted Date: 2010-08-09

Last Posted Date: 2023-10-06

Lead Sponsor: Sherif Farag, MB, BS

Target Recruit Count: 32

Registration Number: NCT01177683

Locations: 🇺🇸
IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸
Metro Health Cancer Care, Wyoming, Michigan, United States
🇺🇸
Community Regional Cancer Center, Indianapolis, Indiana, United States

and more 4 locations

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1

Withdrawn

Conditions: Mantle Cell Lymphoma

First Posted Date: 2010-07-27

Last Posted Date: 2011-03-16

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 20

Registration Number: NCT01170052

Locations: 🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Charité Mitte, Berlin, Germany

Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bendamustine plus bortezomib plus dexamethasone

First Posted Date: 2010-07-23

Last Posted Date: 2013-11-25

Lead Sponsor: Austrian Forum Against Cancer

Target Recruit Count: 79

Registration Number: NCT01168804

Locations: 🇦🇹
Med. University Vienna, Clinic for Internal Medicine 1 (Hematology and Hemostaseology), Vienna, Austria
🇦🇹
Hanusch Hospital Vienna, Vienna, Austria
🇦🇹
Medical University Hospital Graz, Graz, Austria

and more 5 locations

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Drug: Carboplatin
Biological: Rituximab
Drug: Etoposide
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-07-19

Last Posted Date: 2018-12-05

Lead Sponsor: University of Washington

Target Recruit Count: 48

Registration Number: NCT01165112

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bendamustine and Bevacizumab for Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Bendamustine
Drug: Bevacizumab

First Posted Date: 2010-06-29

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT01152203

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Untreated Adult Acute Myeloid Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndrome With Isolated Del(5q)

Interventions: Drug: bendamustine hydrochloride
Drug: idarubicin

First Posted Date: 2010-06-10

Last Posted Date: 2017-08-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 39

Registration Number: NCT01141725

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma
Lymphoma, Large Cell
Diffuse, Mantle Cell Lymphoma, Lymphoma
Follicular Lymphoma
Large B-Cell, Diffuse

Interventions: Drug: SyB L-0501
Drug: Rituximab

First Posted Date: 2010-05-07

Last Posted Date: 2013-07-04

Lead Sponsor: SymBio Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT01118845

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase 2

Completed

Conditions: Nodal Marginal Zone B-cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma

Interventions: Drug: bendamustine hydrochloride
Drug: dexamethasone
Biological: filgrastim
Procedure: leukapheresis
Other: laboratory biomarker analysis
Other: flow cytometry
Drug: etoposide

First Posted Date: 2010-04-26

Last Posted Date: 2017-05-24

Lead Sponsor: University of Washington

Target Recruit Count: 43

Registration Number: NCT01110135

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine hydrochloride injection
Drug: Chlorambucil

First Posted Date: 2010-04-23

Last Posted Date: 2013-08-23

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 147

Registration Number: NCT01109264

Locations: 🇨🇳
Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma (NHL)

Interventions: Drug: Bendamustine hydrochloride
Drug: Ofatumumab

First Posted Date: 2010-04-22

Last Posted Date: 2012-08-28

Lead Sponsor: Cephalon

Target Recruit Count: 50

Registration Number: NCT01108341

Locations: 🇺🇸
Florida Cancer Institute - New Hope, New Port Richey, Florida, United States
🇺🇸
Dublin Hematology Oncology Care P.C., Dublin, Georgia, United States
🇺🇸
Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States

and more 30 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy